Meeting
2021 Gastrointestinal Cancers Symposium
A phase I/II trial to evaluate cabozantinib in patients with advanced hepatocellular carcinoma with Child-Pugh class B cirrhosis after first-line therapy.
Authors
Thomas Enzler
University of Michigan Medicine, Ann Arbor, MI
Thomas Enzler , Neehar Parikh , Chih-Yi Liao , Aparna Kalyan , David Hsieh , Kent A. Griffith , Vaibhav Sahai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
04497038
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr TPS357)
DOI
10.1200/JCO.2021.39.3_suppl.TPS357
Abstract #
TPS357
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
First Author: William Joseph Chapin
Poster
2019 ASCO Annual Meeting
Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
First Author: Robin Kate Kelley
Poster
2019 Gastrointestinal Cancers Symposium
Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.
First Author: Sharlene Gill
Poster
2015 Gastrointestinal Cancers Symposium
A phase II study of palbociclib (PD-0332991) in adult patients with advanced hepatocellular carcinoma.
First Author: Susan Joy Littman